Keros Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD from Q4 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Keros Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount history and growth rate from Q4 2020 to Q4 2023.
  • Keros Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending December 31, 2023 was $6.92M, a 0.06% increase year-over-year.
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $6.92M +$4K +0.06% Dec 31, 2023 10-K 2024-02-28
Q3 2023 $7.29M Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $7.65M Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $8.01M Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $6.91M +$6.86M +12702% Dec 31, 2022 10-K 2023-03-03
Q4 2021 $54K -$26K -32.5% Dec 31, 2021 10-K 2022-03-09
Q3 2021 $76K Sep 30, 2021 10-Q 2021-11-04
Q4 2020 $80K Dec 31, 2020 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.